ZANTAC 75 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zantac 75, and when can generic versions of Zantac 75 launch?
Zantac 75 is a drug marketed by Chattem Sanofi and is included in two NDAs.
The generic ingredient in ZANTAC 75 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zantac 75
A generic version of ZANTAC 75 was approved as ranitidine hydrochloride by SANDOZ on August 29th, 1997.
Summary for ZANTAC 75
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 117 |
Clinical Trials: | 22 |
Patent Applications: | 2,243 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in ZANTAC 75? | ZANTAC 75 excipients list |
DailyMed Link: | ZANTAC 75 at DailyMed |
Recent Clinical Trials for ZANTAC 75
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Food and Drug Administration (FDA) | Phase 1 |
Spaulding Clinical Research LLC | Phase 1 |
Dalhousie University | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for ZANTAC 75
US Patents and Regulatory Information for ZANTAC 75
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chattem Sanofi | ZANTAC 75 | ranitidine hydrochloride | TABLET, EFFERVESCENT;ORAL | 020745-001 | Feb 26, 1998 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Chattem Sanofi | ZANTAC 75 | ranitidine hydrochloride | TABLET;ORAL | 020520-001 | Dec 19, 1995 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZANTAC 75
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Chattem Sanofi | ZANTAC 75 | ranitidine hydrochloride | TABLET;ORAL | 020520-001 | Dec 19, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
Chattem Sanofi | ZANTAC 75 | ranitidine hydrochloride | TABLET;ORAL | 020520-001 | Dec 19, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
Chattem Sanofi | ZANTAC 75 | ranitidine hydrochloride | TABLET;ORAL | 020520-001 | Dec 19, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZANTAC 75
See the table below for patents covering ZANTAC 75 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Cyprus | 1077 | AMINOALKYL FURAN DERIVATIVES | ⤷ Try a Trial |
Spain | 470836 | ⤷ Try a Trial | |
Denmark | 148258 | ⤷ Try a Trial | |
Philippines | 21761 | PHARMACEUTICAL COMPOSITION CONTAINING FORM 2 RANITIDINE HYDROCHLORIDE AND PROCESS OF PREPARATION THEREOF | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |